Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer

Trial Profile

Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs IMC CS4 (Primary)
  • Indications Advanced breast cancer; Prostate cancer
  • Focus Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Dec 2016 Planned number of patients changed from 16 to 36.
    • 12 Dec 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
    • 12 Dec 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top